



Edition: BP 2025 (Ph. Eur. 11.6 update)

Acetazolamide Tablets

[General Notices](#)

Action and use

Carbonic anhydrase inhibitor; diuretic; treatment of glaucoma, ocular hypertension, mountain sickness.

DEFINITION

Acetazolamide Tablets contain Acetazolamide.

The tablets comply with the requirements stated under Tablets and with the following requirements.

Content of acetazolamide, $C_4H_6N_4O_3S_2$

95.0 to 105.0% of the stated amount.

IDENTIFICATION

- A. Shake a quantity of the powdered tablets containing 0.5 g of Acetazolamide with 2 mL of 1M [sodium hydroxide](#) and filter. Neutralise the filtrate with [glacial acetic acid](#), filter and dry the resulting precipitate at 105°. The [infrared absorption spectrum](#) of the residue, [Appendix II A](#), is concordant with the *reference spectrum* of acetazolamide (*RS 002*).
- B. Triturate a quantity of the powdered tablets containing 0.5 g of Acetazolamide with a mixture of 5 mL of [water](#) and 1 mL of 1M [sodium hydroxide](#), transfer to a test tube, add 0.2 g of [zinc powder](#) and 0.5 mL of [hydrochloric acid](#) and immediately place a piece of [lead acetate paper](#) over the mouth of the tube. The paper exhibits a brownish black colour.
- C. To a quantity of the powdered tablets containing 25 mg of Acetazolamide add 5 mL of [water](#), 0.15 mL of 1M [sodium hydroxide](#) and 0.1 mL of [weak copper sulfate solution](#). A greenish blue colour or precipitate is produced.

TESTS

Related substances

Carry out the method for [thin-layer chromatography](#), [Appendix III A](#), using the following solutions.

- (1) Shake a quantity of the powdered tablets containing 50 mg of Acetazolamide for 20 minutes with 10 mL of a mixture of equal volumes of [ethanol \(96%\)](#) and [ethyl acetate](#) and filter.
- (2) Dilute 1 volume of solution (1) to 100 volumes with the same solvent mixture as for solution (1).

CHROMATOGRAPHIC CONDITIONS

- (a) Use as the coating [silica gel GF₂₅₄](#).
- (b) Use a mobile phase freshly prepared as described below. Use the tank without lining the walls and allow to saturate for 1 hour before development.
- (c) Apply 20 µL of each solution.
- (d) Develop the plate to 15 cm.
- (e) After removal of the plate, dry in air and examine under [ultraviolet light \(254 nm\)](#).

MOBILE PHASE

20 volumes of 13.5M [ammonia](#), 30 volumes of [ethyl acetate](#) and 50 volumes of [propan-2-ol](#).

LIMITS

Any [secondary spot](#) in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2) (1%).

ASSAY

Weigh and powder 20 tablets. To a quantity of the powder containing 0.4 g of Acetazolamide add 90 mL of [dimethylformamide](#) and carry out Method II for [non-aqueous titration](#), [Appendix VIII A](#), using 0.1M [tetrabutylammonium hydroxide VS](#) as titrant and determining the end point [potentiometrically](#). Each mL of 0.1M [tetrabutylammonium hydroxide VS](#) is equivalent to 22.22 mg of $C_4H_6N_4O_3S_2$.